Quality of Life in Patients Suffering from Active Exudative Age-Related Macular Degeneration: The EQUADE Study
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Purpose: Age-related macular degeneration (AMD) is the main cause of visual loss in the elderly population. With the use of anti-vascular endothelial growth factor, the visual outcomes of exudative AMD patients have been improved. This study was aimed at assessing the quality of life (QoL) of exudative AMD patients treated with ranibizumab and at determining its drivers in a real-life setting. Methods: We performed a national, cross-sectional, observational survey based on questionnaires sent to members of French associations relative to AMD between December 2012 and March 2013. Patients suffering from exudative AMD with at least one intravitreal injection of ranibizumab within the last 6 months were included. Demographics, AMD characteristics, visual acuity (VA) and past and ongoing treatments were collected. The 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) was self-administered. A multivariate model was used to identify QoL drivers. Results: 416 questionnaires fulfilled the complete criteria for both QoL and cost analyses. The mean age of exudative AMD patients was 78.0 years and bilateral involvement was reported in 60.4%. The overall mean QoL score was 53.4. Mental health, driving and role difficulties were the most widely affected domains. After bivariate analyses, long-term illness status, worse VA and higher number of unpaid aids were associated with worse QoL, with odds ratios of 2.4, 5.2 and 11.6, respectively. The mean cost per year and per patient was 1,741 EUR. The main components of costs were aids and services and the purchase of visual equipment. Conclusions: The main predictors of QoL in exudative AMD patients treated with ranibizumab are VA outcomes, home healthcare and social services provided to the patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most frequent resources accounted for within direct non-medical costs were formal care [34, 38–43, 45] and assistive technologies [34, 37–39, 41–43, 45], followed by transportation [34, 37–39, 42, 45] and subsidies [40–43] (Table 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Nine studies [34, 37–43, 45] reported direct non-medical costs per patient per annum, ranging from $688 to $15,418 (Fig. 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“Of note, only three studies using post-2010 cost data reported annual direct non-medical costs [34, 37, 38].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Development of the 25-list-item National Eye Institute Visual Function Questionnaire
Mangione, C. M. (2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.7.1050 · Cited by 2,230
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies
Ambati, J., Ambati, B. K., Yoo, S. H., Ianchulev, S., & Adamis, A. P. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00030-4 · Cited by 959
Chang, T. S. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.11.1460 · Cited by 239
Cohen, S. Y., Mimoun, G., Oubraham, H., Zourdani, A., Malbrel, C., Queré, S., & Schneider, V. (2013) · Retina · doi:10.1097/iae.0b013e31827b6324 · Cited by 198
Soubrane, G. (2007) · Archives of Ophthalmology · doi:10.1001/archopht.125.9.1249 · Cited by 155
Vélez-Montoya, R., Oliver, S. C. N., Olson, J. L., Fine, S. L., Quiroz-Mercado, H., & Mandava, N. (2013) · Retina · doi:10.1097/iae.0000000000000036 · Cited by 154
Oubraham, H., Cohen, S. Y., Samimi, S., Marotte, D., Bouzaher, I., Bonicel, P., Fajnkuchen, F., & Tadayoni, R. (2011) · Retina · doi:10.1097/iae.0b013e3181de5609 · Cited by 151
Cited by
Finger, R. P., Daïen, V., Eldem, B. M., Talks, J. S., Korobelnik, J., Mitchell, P. L. R., Sakamoto, T., Wong, T. Y., Pantiri, K., & Carrasco, J. (2020) · BMC Ophthalmology · doi:10.1186/s12886-020-01554-2 · Cited by 163
Nagai, N., Suzuki, M., Uchida, A., Kurihara, T., Kamoshita, M., Minami, S., Shinoda, H., Tsubota, K., & Ozawa, Y. (2016) · Scientific Reports · doi:10.1038/srep29619 · Cited by 62
Tuuminen, R., Uusitalo‐Järvinen, H., Aaltonen, V., Hautala, N. M., Kaipiainen, S., Laitamäki, N., Ollila, M., Rantanen, J., Välimäki, S., Sipilä, R., et al. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13501 · Cited by 50
“Two meta-analyses reported a 0.049–0.056% risk for endophthalmitis after intravitreal antiVEFG injections, i.e. about five infections per 10 000 injections (McCannel 2011; Fileta et al. 2014).”
BackgroundInfluentialGale, R. P., Finger, R. P., Eldem, B. M., Aslam, T. M., Barratt, J., Daïen, V., Kodjikian, L., Loewenstein, A., Okada, M., Wong, T. Y., et al. (2022) · Acta Ophthalmologica · doi:10.1111/aos.15201 · Cited by 39
Schippert, A. C., Jelin, E., Moe, M. C., Heiberg, T., & Grov, E. K. (2018) · Gerontology and Geriatric Medicine · doi:10.1177/2333721418801601 · Cited by 33
“Reduction in QoL is associated with wet AMD and has been measured with standardized instruments leaving additional knowledge regarding aspects of the disease (Matamoros et al., 2015; Swamy, Chia, Wang, Rochtchina, & Mitchell, 2009).”
Method
Metadata
- Authors
- Matamoros, E., Maurel, F., Léon, N., Solomiac, A., Bardoulat, I., Joubert, M., Hermans, M., Moser, E., Le Picard, S., Souied, E. H., & Leveziel, N.
- Affiliations
- Centre Hospitalier Universitaire de Poitiers (FR)
- IQVIA (United States) (US)
- Retina France (FR)
- Université Paris-Est Créteil (FR)
- Université de Poitiers (FR)
- Venue
- Ophthalmologica
- Publisher
- S. Karger AG
- Published
- 2015
- Volume
- 234
- Issue
- 3
- Pages
- 151-159
- ISSN
- 0030-3755 (ISSN-L)
- 1423-0267
- OpenAlex
- W1873618078
- Cited by
- 40
- References
- 24
- Citations by year
- 2026: 3 · 2025: 4 · 2023: 4 · 2022: 4 · 2021: 6 · 2020: 7 · 2019: 1 · 2018: 6 · 2017: 2 · 2016: 2
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- creativecommons.org/licenses/by-nc-nd/4.0/ (tdm)
- Locations
- Ophthalmologica (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Retina France
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
- Keywords
- neovascular age-related macular degeneration, quality of life, ranibizumab, anti-VEGF therapy, visual acuity, NEI VFQ-25, mental health, driving impairment, chronic disease, home health care, social services, cost of care, visual aids, elderly patients
- MeSH terms
- Ranibizumab, Aged, Aged, 80 and over, Cross-Sectional Studies, Exudates and Transudates, Female, Humans, Male, Middle Aged, Quality of Life, Surveys and Questionnaires, Visual Acuity, Cost of Illness, Sickness Impact Profile, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quality of Life in Patients Suffering from Active Exudative Age-Related Macular Degeneration: The EQUADE Study. https://app.cochat.ai/papers/10.1159/000433448
- The paper
- Matamoros, E., Maurel, F., Léon, N., Solomiac, A., Bardoulat, I., Joubert, M., Hermans, M., Moser, E., Le Picard, S., Souied, E. H., & Leveziel, N. (2015). Quality of Life in Patients Suffering from Active Exudative Age-Related Macular Degeneration: The EQUADE Study. Ophthalmologica. https://doi.org/10.1159/000433448
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

